Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

McMaster University

$105,000.00

Modelling clonal heterogeneity in brain tumor recurrence: identification of treatment refractory tumor initiating population in human glioblastoma

FY 2015-16

Summary
Human glioblastoma (GBM), a highly malignant grade IV astrocytic tumor, remains incurable despite advances in multimodal therapy. Recent data has implicated GBM heterogeneity in modulating therapy resistance and tumor relapse. At the cellular level, this heterogeneity may be explained by the existence of multiple populations of cancer cells that have acquired stem cell properties, termed brain tumor initiating cells (BTICs). We postulate that different BTIC populations are capable of first initiating the tumor, and later evading therapy to seed the tumor relapse, as they undergo clonal evolution over time in response to various environmental cues including chemo and radiotherapy. Currently, no laboratory model allows researchers to comprehensively profile GBM BTIC populations that evade current therapy, and is responsible for cancer relapse or progression. In this study, we aim to develop a novel model to profile the clonal evolution of treatment naïve GBM BTICs through chemoradiotherapy based on stem cell assays, BTIC marker expression and transcriptome analysis. Using cellular barcoding technology, we will also track clonal populations of GBM cells through our therapy model to understand the dynamics of therapy resistance. Most GBM patients suffer from poor outcomes and relapse leading to death, and researchers currently have limited clinical opportunities to examine specimens from relapsed patients, who very often will not undergo re-operation when their tumors recur. The current research proposal seeks to discover BTIC specific genes through a clinically relevant in vivo model of GBM relapse, for selective targeting of BTIC signalling pathways that specifically drive therapy resistance and tumor relapse in an individual patient. Identifying BTIC-specific therapeutic targets may lead to an improved risk-benefit profile for survivors and an overall improved survivorship for GBM patients.
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
347949
Name
Qazi Maleeha A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Modelling clonal heterogeneity in brain tumor recurrence: identification of treatment refractory tumor initiating population in human glioblastoma
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Brain Tumor Initiating Cells; Cancer Stem Cells; Cell Signalling; Cellular Barcoding; Clonal Evolution; Human-Mouse Xenograft; Therapy Resistance; Treatment Refractory Cells; Tumor Heterogeneity; Tumor Recurrence
Abstract
Human glioblastoma (GBM), a highly malignant grade IV astrocytic tumor, remains incurable despite advances in multimodal therapy. Recent data has implicated GBM heterogeneity in modulating therapy resistance and tumor relapse. At the cellular level, this heterogeneity may be explained by the existence of multiple populations of cancer cells that have acquired stem cell properties, termed brain tumor initiating cells (BTICs). We postulate that different BTIC populations are capable of first initiating the tumor, and later evading therapy to seed the tumor relapse, as they undergo clonal evolution over time in response to various environmental cues including chemo and radiotherapy. Currently, no laboratory model allows researchers to comprehensively profile GBM BTIC populations that evade current therapy, and is responsible for cancer relapse or progression. In this study, we aim to develop a novel model to profile the clonal evolution of treatment naïve GBM BTICs through chemoradiotherapy based on stem cell assays, BTIC marker expression and transcriptome analysis. Using cellular barcoding technology, we will also track clonal populations of GBM cells through our therapy model to understand the dynamics of therapy resistance. Most GBM patients suffer from poor outcomes and relapse leading to death, and researchers currently have limited clinical opportunities to examine specimens from relapsed patients, who very often will not undergo re-operation when their tumors recur. The current research proposal seeks to discover BTIC specific genes through a clinically relevant in vivo model of GBM relapse, for selective targeting of BTIC signalling pathways that specifically drive therapy resistance and tumor relapse in an individual patient. Identifying BTIC-specific therapeutic targets may lead to an improved risk-benefit profile for survivors and an overall improved survivorship for GBM patients.
Competitiondate
201510
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Qazi, Maleeha A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
McMaster University - $105,000 Grant (2015-16) | Canada Spends